{"id":3957,"date":"2026-01-23T11:37:19","date_gmt":"2026-01-23T10:37:19","guid":{"rendered":"https:\/\/reseau-amylose.org\/rechercheamylose\/?page_id=3957"},"modified":"2026-01-27T15:48:21","modified_gmt":"2026-01-27T14:48:21","slug":"recherche-amylose-essai-triton-cm-nucresiran","status":"publish","type":"page","link":"http:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/","title":{"rendered":"Essai TRITON-CM : nucresiran dans l’amylose \u00e0 transthyr\u00e9tine ATTR"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Essai TRITON-CM : nucresiran dans l'amylose \u00e0 transthyr\u00e9tine - ATTR<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

L\u2019essai TRITON-CM<\/strong> est une \u00e9tude clinique internationale de phase 3 \u00e9valuant l\u2019efficacit\u00e9 et la tol\u00e9rance du nucresiran<\/strong> chez des patients atteints d\u2019amylose \u00e0 transthyr\u00e9tine (ATTR) avec cardiomyopathie.<\/p>

TRITON-CM compare le nucresiran au traitement de r\u00e9f\u00e9rence (Standard of Care \u2013 SoC)<\/strong> utilis\u00e9 dans chaque pays participant, incluant principalement le tafamidis<\/strong>, l\u2019acoramidis<\/strong>, ou un placebo<\/strong> dans de rares pays o\u00f9 aucun traitement sp\u00e9cifique n\u2019est disponible.<\/p>

L\u2019objectif global est d\u2019inclure 1\u202f250 patients<\/strong>, randomis\u00e9s selon un ratio 2:1<\/strong> (2 patients recevant le nucresiran pour 1 patient recevant le traitement de r\u00e9f\u00e9rence).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Objectif de l\u2019\u00e9tude<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

L\u2019objectif principal de TRITON-CM est d\u2019\u00e9valuer si le nucresiran permet d\u2019am\u00e9liorer l\u2019\u00e9volution clinique des patients atteints d’amylose \u00e0 transthyr\u00e9tine, en comparaison au traitement de r\u00e9f\u00e9rence, tout en \u00e9valuant sa s\u00e9curit\u00e9 d\u2019emploi.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Le traitement \u00e0 l\u2019\u00e9tude : le nucresiran<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Le nucresiran<\/strong> est un ARN interf\u00e9rent (ARNi) de derni\u00e8re g\u00e9n\u00e9ration<\/strong>, con\u00e7u pour r\u00e9duire la production de la transthyr\u00e9tine (TTR), prot\u00e9ine responsable de la formation des d\u00e9p\u00f4ts amylo\u00efdes.<\/p>

Les r\u00e9sultats de la phase 1<\/strong>, \u00e0 la dose de 300 mg<\/strong> retenue pour la phase 3, ont montr\u00e9 :<\/p>

  • Une r\u00e9duction de plus de 90 % de la TTR circulante<\/strong><\/li>
  • Une faible variabilit\u00e9 interindividuelle<\/strong> de la r\u00e9ponse<\/li>
  • La possibilit\u00e9 d\u2019un espacement des injections \u00e0 une administration tous les 6 mois<\/strong>, am\u00e9liorant le confort et l\u2019adh\u00e9sion des patients.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t

    Sch\u00e9ma de l\u2019\u00e9tude<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"recherche-amylose\/essai-triton-cm-nucresiran\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t

    Principaux crit\u00e8res d\u2019inclusion<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    Les principaux crit\u00e8res d\u2019inclusion comprennent :<\/p>

    • \u00c2ge compris entre 18 et 85 ans<\/strong><\/li>
    • Diagnostic document\u00e9 d\u2019amylose \u00e0 transthyr\u00e9tine (ATTR)<\/strong> avec atteinte cardiaque
      • Forme h\u00e9r\u00e9ditaire<\/strong> ou sauvage<\/strong><\/li><\/ul><\/li>
      • Ant\u00e9c\u00e9dents m\u00e9dicaux d\u2019insuffisance cardiaque<\/strong>, d\u00e9finis par :
        • Au moins une hospitalisation ant\u00e9rieure pour insuffisance cardiaque ou<\/strong><\/li>
        • Des signes cliniques d\u2019insuffisance cardiaque (avec ou sans hospitalisation) n\u00e9cessitant un traitement par diur\u00e9tique<\/li><\/ul><\/li><\/ul>

          \u00c0 ce stade, le traitement requis repose principalement sur les diur\u00e9tiques de l\u2019anse<\/strong>, avec une \u00e9volution attendue des crit\u00e8res pour inclure notamment les inhibiteurs de SGLT2 (ISGLT2)<\/strong>.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

          \n\t\t\t\t\t\t
          \n\t\t\t\t\t
          \n\t\t\t
          \n\t\t\t\t\t\t
          \n\t\t\t\t
          \n\t\t\t\t\t

          Centres investigateurs en France<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
          \n\t\t\t\t
          \n\t\t\t\t\t\t\t\t\t

          L\u2019\u00e9tude TRITON-CM est conduite dans de nombreux centres experts fran\u00e7ais, avec les investigateurs principaux suivants :<\/p>

          1. CHU de Toulouse \u2013 H\u00f4pital de Rangueil<\/strong> : Olivier LAIREZ\u00a0(ouvert)<\/em><\/p><\/li>

          2. CHU de Rouen \u2013 H\u00f4pital Charles-Nicolle<\/strong> : Charles FAUVEL\u00a0(ouvert)<\/em><\/p><\/li>

          3. CHU de Nantes \u2013 H\u00f4pital Nord Laennec<\/strong> : Nicolas PIRIOU\u00a0(ouvert)<\/em><\/p><\/li>

          4. CHU de Rennes \u2013 H\u00f4pital Pontchaillou<\/strong> : Erwan DONAL\u00a0(ouvert)<\/em><\/p><\/li>

          5. CHRU de Tours \u2013 H\u00f4pital Trousseau<\/strong> : Anne BERNARD\u00a0(ouvert)<\/em><\/p><\/li>

          6. CHU de Montpellier \u2013 H\u00f4pital Arnaud de Villeneuve<\/strong> : Fran\u00e7ois ROUBILLE\u00a0(ouvert)<\/em><\/p><\/li>

          7. CHU de Bordeaux \u2013 H\u00f4pital Haut-L\u00e9v\u00eaque<\/strong> : Patricia R\u00c9ANT\u00a0(ouvert)<\/em><\/p><\/li>

          8. AP-HM \u2013 H\u00f4pital de la Timone<\/strong> : Gilbert HABIB\u00a0(ouvert)<\/em><\/p><\/li>

          9. CHU Grenoble Alpes \u2013 H\u00f4pital Michallon<\/strong> : Gilles BARONE-ROCHETTE\u00a0(ouvert)<\/em><\/p><\/li>

          10. CHU de Reims \u2013 H\u00f4pital Robert-Debr\u00e9<\/strong> : J\u00e9r\u00f4me COSTA\u00a0(ouvert)<\/em><\/p><\/li>

          11. AP-HP \u2013 H\u00f4pital Bichat \u2013 Claude-Bernard<\/strong> : Vincent ALGALARRONDO\u00a0(pr\u00e9vu mi-f\u00e9vrier)<\/em><\/p><\/li>

          12. CHU de Martinique<\/strong> : Astrid MONFORT\u00a0(pr\u00e9vu mi-f\u00e9vrier)<\/em><\/p><\/li>

          13. AP-HP \u2013 H\u00f4pital Europ\u00e9en Georges-Pompidou<\/strong> : Albert HAGEGE\u00a0(pr\u00e9vu mi-f\u00e9vrier)<\/em><\/p><\/li>

          14. AP-HP \u2013 H\u00f4pital Henri-Mondor<\/strong> : Thibaud DAMY\u00a0(pr\u00e9vu fin f\u00e9vrier)<\/em><\/p><\/li>

          15. CHU Dijon Bourgogne \u2013 H\u00f4pital Fran\u00e7ois-Mitterrand<\/strong> : Romain DIDIER\u00a0(pr\u00e9vu fin f\u00e9vrier)<\/em><\/p><\/li>

          16. CHU de Strasbourg \u2013 Nouvel H\u00f4pital Civil<\/strong> : Jean-Jacques VON HUNOLSTEIN\u00a0(pr\u00e9vu fin f\u00e9vrier)<\/em><\/p><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

            \n\t\t\t\t\t\t
            \n\t\t\t\t\t
            \n\t\t\t
            \n\t\t\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t\t\t

            L’essai TRITON-CM repr\u00e9sente une \u00e9tape majeure dans le d\u00e9veloppement de nouvelles strat\u00e9gies th\u00e9rapeutiques pour l’amylose \u00e0 transthyr\u00e9tine. Gr\u00e2ce \u00e0 une r\u00e9duction marqu\u00e9e et prolong\u00e9e de la TTR, le nucresiran pourrait constituer une avanc\u00e9e significative pour les patients, tout en simplifiant le sch\u00e9ma d\u2019administration.<\/p>

            Pour toute question, il est recommand\u00e9 de contacter l’un des centres investigateurs.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

            Essai TRITON-CM : nucresiran dans l’amylose \u00e0 transthyr\u00e9tine – ATTR L\u2019essai TRITON-CM est une \u00e9tude clinique internationale de phase 3 \u00e9valuant l\u2019efficacit\u00e9 et la tol\u00e9rance du nucresiran chez des patients atteints d\u2019amylose \u00e0 transthyr\u00e9tine (ATTR) avec cardiomyopathie. TRITON-CM compare le nucresiran au traitement de r\u00e9f\u00e9rence (Standard of Care \u2013 SoC) utilis\u00e9 dans chaque pays participant, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-3957","page","type-page","status-publish","hentry"],"yoast_head":"\nEssai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR<\/title>\n<meta name=\"description\" content=\"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR\" \/>\n<meta property=\"og:description\" content=\"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/\" \/>\n<meta property=\"og:site_name\" content=\"R\u00e9seau Amylose Recherche\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T14:48:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d-768x768.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/\",\"url\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/\",\"name\":\"Essai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR\",\"isPartOf\":{\"@id\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d-768x768.png\",\"datePublished\":\"2026-01-23T10:37:19+00:00\",\"dateModified\":\"2026-01-27T14:48:21+00:00\",\"description\":\"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.\",\"breadcrumb\":{\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage\",\"url\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d.png\",\"contentUrl\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d.png\",\"width\":1024,\"height\":1024,\"caption\":\"recherche-amylose\/essai-triton-cm-nucresiran\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essai TRITON-CM : nucresiran dans l’amylose \u00e0 transthyr\u00e9tine ATTR\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/#website\",\"url\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/\",\"name\":\"R\u00e9seau Amylose Recherche\",\"description\":\"Centre de r\u00e9f\u00e9rence des amyloses cardiaques\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/reseau-amylose.org\/rechercheamylose\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Essai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR","description":"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/","og_locale":"fr_FR","og_type":"article","og_title":"Essai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR","og_description":"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.","og_url":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/","og_site_name":"R\u00e9seau Amylose Recherche","article_modified_time":"2026-01-27T14:48:21+00:00","og_image":[{"url":"https:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d-768x768.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/","url":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/","name":"Essai TRITON-CM \u2013 Nucresiran et amylose \u00e0 transthyr\u00e9tine - ATTR","isPartOf":{"@id":"http:\/\/reseau-amylose.org\/rechercheamylose\/#website"},"primaryImageOfPage":{"@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage"},"image":{"@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage"},"thumbnailUrl":"https:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d-768x768.png","datePublished":"2026-01-23T10:37:19+00:00","dateModified":"2026-01-27T14:48:21+00:00","description":"Essai clinique de phase 3 TRITON-CM \u00e9valuant le nucresiran chez les patients atteints de cardiomyopathie amylo\u00efde ATTR. Crit\u00e8res et centres.","breadcrumb":{"@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#primaryimage","url":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d.png","contentUrl":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-content\/uploads\/sites\/3\/2026\/01\/Gemini_Generated_Image_g43d71g43d71g43d.png","width":1024,"height":1024,"caption":"recherche-amylose\/essai-triton-cm-nucresiran"},{"@type":"BreadcrumbList","@id":"https:\/\/reseau-amylose.org\/rechercheamylose\/recherche-amylose-essai-triton-cm-nucresiran\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"http:\/\/reseau-amylose.org\/rechercheamylose\/"},{"@type":"ListItem","position":2,"name":"Essai TRITON-CM : nucresiran dans l’amylose \u00e0 transthyr\u00e9tine ATTR"}]},{"@type":"WebSite","@id":"http:\/\/reseau-amylose.org\/rechercheamylose\/#website","url":"http:\/\/reseau-amylose.org\/rechercheamylose\/","name":"R\u00e9seau Amylose Recherche","description":"Centre de r\u00e9f\u00e9rence des amyloses cardiaques","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/reseau-amylose.org\/rechercheamylose\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"acf":[],"_links":{"self":[{"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/pages\/3957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/comments?post=3957"}],"version-history":[{"count":25,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/pages\/3957\/revisions"}],"predecessor-version":[{"id":3986,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/pages\/3957\/revisions\/3986"}],"wp:attachment":[{"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/media?parent=3957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/categories?post=3957"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/reseau-amylose.org\/rechercheamylose\/wp-json\/wp\/v2\/tags?post=3957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}